Skip to main content

Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature

European Journal of Clinical Pharmacology volume 60, pages 67–74 (2004)Cite this article

Abstract

Aim

To assess the evidence supporting early antibiotic treatment in asymptomatic cystic fibrosis (CF) patients colonised by Pseudomonas aeruginosa (PA).

Methods

We carried out a computerised (Medline, Embase) and hand search of journals for suitable publications. All English-language clinical studies regarding the efficacy of early antibiotic treatment on PA colonisation in asymptomatic patients were considered. Each eligible publications fitting these criteria were assessed for the following outcome measures: frequency of positive PA cultures; serum level of precipitating antibodies; lung function; survival; number of hospitalisations; adverse effects and resistance to antibiotics.

Results

Of the 11 studies eventually considered, 3 were randomised—2 versus placebo— and 8 were cohort studies—2 of which had historical controls. Overall, 309 patients (population range 7–91 patients) were recruited. There was a high variability between the individual studies for age, outcome measures, duration of follow-up (1 to 44 months) and treatment (three studies used only aerosol tobramycin, one colistin, four aerosol colistin plus oral ciprofloxacin, one used intravenous treatment and two miscellaneous therapy). An overall evaluation indicated that early antibiotic treatment can reduce the number of positive cultures and the anti-PA antibody titre. In one study, FEV1 was better in the treated group (oral ciprofloxacin and nebulised colistin) than in historical controls, while in one placebo-controlled trial, no effect on lung function was shown after 1 year of tobramycin inhalation. Collateral effects and bacterial resistance were not increased. The short follow-up did not allow definite conclusions with regard to the long-term progression of respiratory insufficiency or survival.

Conclusions

Evidence was found that antibiotic treatment can reduce the rate of positive cultures and of anti-PA antibody titres in asymptomatic CF patients with newly isolated PA. Different therapeutic options have not been directly compared: a multi-centre comparative study needs to be carried out.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. FitzSimmons SC (1993) The changing epidemiology of cystic fibrosis. J Pediatr 122:1–9

    CAS  PubMed  Google Scholar 

  2. Cystic fibrosis foundation (2001) Patient registry 2000 (annual report). Cystic Fibrosis Foundation, Bethesda

  3. Conese M, Assael BM (2001) Bacterial infections and inflammation in the lungs of cystic fibrosis patients. Pediatr Infect Dis J 20:207–213

    Article  CAS  PubMed  Google Scholar 

  4. Kerem E (1997) The role of Pseudomonas aeruginosa in the pathogenesis of lung disease in cystic fibrosis: more questions than answers. Pediatr Pulmonol Suppl 16:265–266

    CAS  PubMed  Google Scholar 

  5. Kerem E, Corey M, Gold R, Levison H (1990) Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116:714–719

    CAS  PubMed  Google Scholar 

  6. Aebi C, Bracher R, Liechti-Gallati S, Tschappeler H, Rudeberg A, Kraemer R (1995) The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis: prognostic significance. Eur J Pediatr 154[Suppl 4]:S69–S73

    Google Scholar 

  7. Winnie GB, Cowan RG (1991) Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlation between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 10:91–100

    Google Scholar 

  8. Pamukcu A, Bush A, Buchdahl R (1995) Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 19:10–15

    CAS  PubMed  Google Scholar 

  9. Kosorok MR, Zeng L, West SHE et al (2001) Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 32:277–287

    Article  CAS  PubMed  Google Scholar 

  10. Nixon GM, Armstrong DS, Carzino R et al (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138:699–704

    Article  CAS  PubMed  Google Scholar 

  11. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91–100

    Article  PubMed  Google Scholar 

  12. Borsje P, de Jongste JC, Mouton JW, Tiddens HAWM (2000) Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatr Pulmonol 30:368–376

    Article  CAS  PubMed  Google Scholar 

  13. Valerius NH, Koch C, Hoiby N (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725–726

    Article  CAS  PubMed  Google Scholar 

  14. Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC (1993) Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 82:308–309

    CAS  PubMed  Google Scholar 

  15. Frederiksen B, Koch C, Hoiby N (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330–335

    Article  CAS  PubMed  Google Scholar 

  16. Wiesemann HG, Steinkamp G, Ratjen F et al (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25:88–92

    Article  CAS  PubMed  Google Scholar 

  17. Griese M, Muller I, Reinhardt D (2002) Eradication of initial Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Eur J Med Res 7:79–80

    PubMed  Google Scholar 

  18. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M et al (2003) Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 167:841–849

    Article  PubMed  Google Scholar 

  19. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH (1985) Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1:865

    Article  CAS  Google Scholar 

  20. Steinkamp G, Tummler B, Malottke R, von der Hardt H (1989) Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 64:1022–1028

    CAS  PubMed  Google Scholar 

  21. Ratjen F, Doring G, Nilolaizik WH (2001) Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358:983–984

    Article  CAS  PubMed  Google Scholar 

  22. Taccetti G, Repetto T, Procopio E, Farina S, Campana S (2002) Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients. Lancet 359:625–626

    Article  PubMed  Google Scholar 

  23. Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gerardin M, Brahimi N, Navarro J, Bingen E (2001) Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation. Pediatr Pulmonol 32:288–292

    Article  CAS  PubMed  Google Scholar 

  24. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, Touw DJ for the Consensus Committee (2000) Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 16:749–767

    Article  CAS  PubMed  Google Scholar 

  25. Ratjen F, Doring G (2003) Cystic fibrosis. Lancet 361:681–689

    Article  CAS  PubMed  Google Scholar 

  26. Lang AB, Schaad UB, Rudeberg A et al (1995) Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunisation on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 127:711–717

    CAS  PubMed  Google Scholar 

  27. Rabin HR, Wohl ME (1997) The preservation of function: treatment of new acquisition of a pathogen. Pediatr Pulmonol 23:323–324

    Article  CAS  PubMed  Google Scholar 

  28. Spilker B (1991) Guide to clinical trials. New York: Raven:35–36

  29. Conway SP, Pond MN, Hamnett T, Watson A (1996). Compliance with treatment in adult patients with cystic fibrosis. Thorax 51:29–33

    CAS  PubMed  Google Scholar 

  30. Conway SP (1999) Evidence for using nebulised antibiotics in cystic fibrosis. Arch Dis Child 80:307–309

    CAS  PubMed  Google Scholar 

  31. Burns JL, Van Dalfsen JM, Shawar RM et al (1999) Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190–1196

    Article  CAS  PubMed  Google Scholar 

  32. Cheer SM, Waugh J, Noble S (2003) Inhaled tobramycin (TOBI). A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 63:2501–2520

    CAS  PubMed  Google Scholar 

  33. Anonymous (2001) TOBI prescribing information. CHIRON Corporation, Emeryville, CA

  34. Ramsey BW, Boat TF (1994) Outcome measures for clinical trials in cystic fibrosis. J Pediatr 124:177–192

    CAS  PubMed  Google Scholar 

  35. Morgan WJ, Butler SM, Johnson CA et al (1999) Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 28:231–241

    Article  CAS  PubMed  Google Scholar 

  36. Cheng K, Smyth RL, Motley J, O’Hea U, Ashby D (2000) Randomized controlled trials in cystic fibrosis (1966–1997) categorized by time, design, and intervention. Pediatr Pulmonol 29:1–7

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors wish to thank Judy Moss for the revision of the manuscript.

Author information

Affiliations

  1. Department of Paediatrics, Regional Centre for Cystic Fibrosis, IRCCS Burlo Garofolo, Via dell’Istria 65/1, 34100 , Trieste, Italy

    Federico Marchetti & Luisella Giglio

  2. Department of Paediatrics, Cosenza City Hospital, Cosenza, Italy

    Manila Candusso

  3. Department of Paediatrics, Gorizia and Monfalcone Hospital, Italy

    Dino Faraguna

  4. Regional Centre for Cystic Fibrosis, Verona and University of Milan Medical School, Italy

    Baroukh M. Assael

Authors
  1. Federico Marchetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luisella Giglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manila Candusso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dino Faraguna
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baroukh M. Assael
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Marchetti.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marchetti, F., Giglio, L., Candusso, M. et al. Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature. Eur J Clin Pharmacol 60, 67–74 (2004). https://doi.org/10.1007/s00228-004-0735-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-004-0735-2

Keywords

  • Cystic fibrosis
  • Pseudomonas aeruginosa
  • Bacterial colonisation